glp-1-ra Indications for GLP-1/GIP RA Summary Sheet and Beyond! GLP-1 prescription trends through March

Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular CellsRenoprotection in Diabetic Nephropathy

Notably, research indicates that individuals most interested in trying GLP-1 medications, and willing to accept common side effects, are those who report greater body shame, body surveillance, weight concerns, anti-fat bias, disordered eating behaviors, and higher BMIs, alongside lower body appreciation and body neutrality (Markey et al., 2025)

95% CI, 0.100.34

[DOI] [PMC free article] [PubMed] [Google Scholar] 51.Lesauter J., Hoque N., Weintraub M., Pfaff D.W., Silver R

Noom expands its GLP-1 range with 'microdose' package Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price

Under the terms of the deal, Novo Nordisk and Eli Lilly have also agreed to sell their GLP-1 drugs directly to patients for roughly $350 for a month's supply, the White House added